Posttraumatic stress disorder (PTSD) is the third most common psychiatric diagnosis among Veterans seen in the Veterans Health Administration (VHA). PTSD can be debilitating, leading to a decline in quality of life and causing significant medical, mental health, interpersonal, and social impairment.
First-line treatments for PTSD include psychotherapy and pharmacotherapy, or a combination of the two. However, many patients do not respond to these therapies. Stellate ganglion blocks (SGB), also called cervical sympathetic blocks, are emerging as an alternative for individuals with PTSD who have not fully responded to conventional therapies.